Browsing ICR Divisions by author "O'Brien, Mary"
Now showing items 1-7 of 7
-
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
Fendler, A; Shepherd, STC; Au, L; Wilkinson, KA; Wu, M; et al. (NATURE PORTFOLIO, 2021-10-27) -
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
Faivre-Finn, C; Snee, M; Ashcroft, L; Appel, W; Barlesi, F; et al. (2017-08)Background Concurrent chemoradiotherapy is the standard of care in limited-stage small-cell lung cancer, but the optimal radiotherapy schedule and dose remains controversial. The aim of this study was to establish a standard ... -
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.
Reck, M; Rodríguez-Abreu, D; Robinson, AG; Hui, R; Csőszi, T; et al. (2021-04-19)Purpose We report the first 5-year follow-up of any first-line phase III immunotherapy trial for non-small-cell lung cancer (NSCLC). KEYNOTE-024 (ClinicalTrials.gov identifier: NCT02142738) is an open-label, randomized ... -
Investigating the efficacy of osimertinib and crizotinib in phase 3 clinical trials on anti-cancer treatment-induced cardiotoxicity: are real-world studies the way forward?
Kobat, H; Elkonaissi, I; Foreman, E; O'Brien, M; Dorak, MT; et al. (SAGE PUBLICATIONS LTD, 2022-02-15)BACKGROUND.: Oncology clinical trials demonstrate the risk of cardiotoxicity but are not sufficient to reveal the true risk. In this article, we compared the incidence of cardiotoxicity of crizotinib and osimertinib from ... -
Molecular Adequacy of Image-Guided Rebiopsies for Molecular Retesting in Advanced Non-Small Cell Lung Cancer: A Single-Center Experience.
Tokaca, N; Barth, S; O'Brien, M; Bhosle, J; Fotiadis, N; et al. (2018-01)Introduction In the era of biomarker-driven systemic therapy for advanced NSCLC, the role of routine repeated biopsies for decision making outside EGFR-mutant disease remains unproven. We report our center's experience of ... -
Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform.
Morfouace, M; Novello, S; Stevovic, A; Dooms, C; Janžič, U; et al. (NATURE PORTFOLIO, 2022-05-18)Access to a comprehensive molecular alteration screening is patchy in Europe and quality of the molecular analysis varies. SPECTAlung was created in 2015 as a pan-European screening platform for patients with thoracic ... -
Targeting the PD-1/PD-L1 axis in non-small cell lung cancer.
Kumar, R; Collins, D; Dolly, S; McDonald, F; O'Brien, MER; et al.The last decade has witnessed rapid advances in the discovery and development of immune checkpoint inhibitors in cancer medicine, particularly drugs targeting programmed cell death 1 (PD-1) and programmed cell death ligand ...